Navigation Links
BioLife Solutions Announces Expanded Customer Base in the High Growth Regenerative Medicine Market
Date:6/1/2011

BOTHELL, Wash., June 1, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today issued an update on the growing number and quality of life science organizations using the Company's products.   These customers are all now purchasing HypoThermosol® and/or CryoStor® to support the development of new regenerative medicine products and therapies.  

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Mike Rice, Chairman and CEO, commented on the growing adoption of BioLife's best-in-class HypoThermosol storage/shipping media and CryoStor freeze media by stating, "We continue to acquire new regenerative medicine customers who are aware of growing regulatory oversight of reagents used in the manufacturing, storage, and delivery processes of novel cell- and tissue-based products.  Our GMP-manufactured, serum-free, protein-free biopreservation media products have a robust quality profile and proven superior preservation efficacy across a broad spectrum of cell and tissue types.  The cost, quality, and performance of our products are all highly aligned with the requirements of the regenerative medicine market."  

Now totaling more than several hundred accounts, BioLife's regenerative medicine customer base is comprised of private and public companies and hospital-based transplant centers including Cardio 3 Biosciences, Children's Cancer Research Institute (Vienna, Austria), DCPrime BV, and Intercytex Ltd.

MedMarket Diligence, LLC, estimates that the current worldwide market for regenerative medicine products and services is growing at 20% annually.  Scientia Advisors, a biotech and medical consulting firm, estimates that the market for regenerative medicine technologies that repair the body could swell to $15-20 billion over the next 15 years. Axis Research Mind estimates the global market value for cryopreservation equipment used in the stem cells industry to be worth $2.2 billion by 2015, representing a compound annual growth rate of about 24%. Freezers represent more than half of the cryopreservation equipment market value, with biopreservation reagents accounting for close to 20% of the total market.  Accordingly, BioLife's addressable market is estimated at nearly $450 million in 2015.

Rice continued, "As regulatory scrutiny increases, we expect pre-formulated biopreservation media products such as our HypoThermosol and CryoStor to continue to displace 'home-brew' preservation cocktails.  While the regenerative medicine market is still in an early phase, our technologies are embedded into numerous clinical trial stage products and we see significant upside in the Company's financial operations from fulfilling potential increased product demand, should our customers' products gain regulatory and marketing approvals."

BioLife recently exhibited at the 17th International Society for Cellular Therapy Annual Meeting in Rotterdam, Netherlands.  Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, presented a tutorial titled, Biopreservation and Stability Considerations for Cellular Therapies – Clinical Applications of HypoThermosol® and CryoStor® as Ancillary or Excipient Reagents.  In this presentation, Dr. Mathew provided examples of customer adoption of BioLife's patented biopreservation media products and their underlying scientific foundation.  The presentation may be viewed here: http://www.biolifesolutions.com/wp-content/uploads/ISCT-2011-BioLife-Tutorial.pdf.  The Spring 2011 issue of BioPreservation Today®, which includes listings of development stage regenerative medicine applications incorporating CryoStor and HypoThermosol, can be found here: http://www.biolifesolutions.com/wp-content/uploads/BPT-Spring2011.pdf.

About BioLife Solutions, Inc.:Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) media products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development. The Company's proprietary HypoThermosol and CryoStor platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death.  US FDA Master Files are available for cross-reference. BioLife's enabling technology provides research and clinical customers significantly extended storage stability and improved post-preservation viability and recovery of cells, tissues, and organs. For more information please visit www.biolifesolutions.com.

Safe Harbor Statement

This shareholder communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the "Company") and its future operating results, strategies, and product development plans. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from the results expressed or implied in these forward-looking statements. Factors that may cause or contribute to such differences are more fully discussed, as are other factors, in Part I, Item1A. "Risk Factors" of the Company's Form 10-K for the fiscal year ended December 31, 2010, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as may be legally necessary, even if the Company's estimates should change.Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Announces Record Quarterly Revenue
2. BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
3. Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Zen Holding Corp. Signs LOI to Acquire Millennium Healthcare Solutions Inc.
6. Sales Agreement with GHX Adds Certain GHX Cost Saving and Revenue-Increasing Solutions to Medical Surgical Solutions Product Offerings
7. Elekta to Demonstrate Advanced Solutions for Managing Cancer Safely and Effectively at ESTRO 2011
8. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
9. Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market
10. OnPoint Medical Diagnostics, Inc. and Vertical Health Solutions, Inc. Complete Reverse Merger
11. United Imaging Healthcare Leverages Samplifys Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):